• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

    2/4/22 3:03:52 PM ET
    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BLI alert in real time by email
    SC 13G/A 1 d276133dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2

     

     

    BERKELEY LIGHTS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    084310101

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 084310101    13G    Page 2 of 9

     

      1.    

      NAMES OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Igor Y. Khandros

      2.    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.    

      SEC USE ONLY

     

      4.    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      UNITED STATES

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

        5.     

      SOLE VOTING POWER

     

      0

      6.     

      SHARED VOTING POWER

     

      8,783,384

      7.     

      SOLE DISPOSITIVE POWER

     

      0

      8.     

      SHARED DISPOSITIVE POWER

     

      8,783,384

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,783,384

    10.    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11.    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.0% based on 67,474,697 shares of Common Stock outstanding as of October 29, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021.

    12.    

      TYPE OF REPORTING PERSON

     

      IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT!


    CUSIP No. 084310101    13G    Page 3 of 9

     

      1.    

      NAMES OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Khandros-Bloch Revocable Trust U/A/D January 24, 1997

      2.    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.    

      SEC USE ONLY

     

      4.    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

        5.     

      SOLE VOTING POWER

     

      0

      6.     

      SHARED VOTING POWER

     

      8,783,384

      7.     

      SOLE DISPOSITIVE POWER

     

      0

      8.     

      SHARED DISPOSITIVE POWER

     

      8,783,384

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,783,384

    10.    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11.    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.0% based on 67,474,697 shares of Common Stock outstanding as of October 29, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021.

    12.    

      TYPE OF REPORTING PERSON

     

      OO (Trust)

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT!


    CUSIP No. 084310101    13G    Page 4 of 9

     

      1.    

      NAMES OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Susan Bloch

      2.    

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.    

      SEC USE ONLY

     

      4.    

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      UNITED STATES

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

        5.     

      SOLE VOTING POWER

     

      0

      6.     

      SHARED VOTING POWER

     

      8,783,384

      7.     

      SOLE DISPOSITIVE POWER

     

      0

      8.     

      SHARED DISPOSITIVE POWER

     

      8,783,384

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,783,384

    10.    

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11.    

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.0% based on 67,474,697 shares of Common Stock outstanding as of October 29, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021.

    12.    

      TYPE OF REPORTING PERSON

     

      IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT!


    CUSIP No. 084310101    13G    Page 5 of 9

     

    Item 1(a).

    The name of the issuer is Berkeley Lights, Inc.

     

    Item 1(b).

    The address of the principal executive offices of the issuer is 5858 Horton Street, Suite 320, Emeryville, California 94608.

     

    Item 1(c).

    Name of Person Filing:

     

     

    This statement on Schedule 13G is being filed pursuant to Rule 13d-1(d) under the Securities Exchange Act of 1934, as amended, by Igor Y. Khandros, the Khandros-Bloch Revocable Trust U/A/D January 24, 1997 and Susan Bloch (the “Reporting Persons”).

     

    Item 1(d).

    Address of Principal Business Office or, if none, Residence:

     

     

    The address of each of the Reporting Persons is c/o Nutcracker Therapeutics, Inc., 5858 Horton Street, Emeryville, California 94608.

     

    Item 1(e).

    Citizenship:

     

     

    Igor Y. Khandros and Susan Bloch are each citizens of the United States. The Khandros-Bloch Revocable Trust U/A/D January 24, 1997 was formed under the laws of the State of California.

     

    Item 1(f).

    Title of Class of Securities:

     

     

    Common Stock, par value $0.00005 per share

     

    Item 1(g).

    CUSIP Number:

     

     

    084310101    

     

    Item 2.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


    CUSIP No. 084310101    13G    Page 6 of 9

     

    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 3.

    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: 8,783,384.

     

      (b)

    Percent of class: 13.0% based on 67,474,697 shares of Common Stock outstanding as of October 29, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote 0.

     

      (ii)

    Shared power to vote or to direct the vote 8,783,384.

     

      (iii)

    Sole power to dispose or to direct the disposition of 0.

     

      (iv)

    Shared power to dispose or to direct the disposition of 8,783,384.

    All shares reported in this statement are held in the name of the Khandros-Bloch Revocable Trust U/A/D January 24, 1997. Igor Y. Khandros and Susan Bloch are co-trustees of such trust.

     

    Item 4.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.


    CUSIP No. 084310101    13G    Page 7 of 9

     

    Item 5.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 6.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 8.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 9.

    Certifications

    Not applicable.

    Exhibits

     

    Exhibit 99.1    Agreement Regarding Joint Filing of Statements on Schedule 13G


    CUSIP No. 084310101    13G    Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 4, 2022

    Date

    /s/ Igor Y. Khandros

    Igor Y. Khandros

    Individually and as Trustee of the Khandros-Bloch Revocable Trust U/A/D January 24, 1997

    February 4, 2022

    Date

    /s/ Susan Bloch

    Susan Bloch

    Individually and as Trustee of the Khandros-Bloch Revocable Trust U/A/D January 24, 1997

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations.

    (See 18 U.S.C. 1001)

    Get the next $BLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLI

    DatePrice TargetRatingAnalyst
    8/10/2022$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2022Buy → Neutral
    BTIG Research
    8/10/2022$12.00 → $8.00Overweight → Neutral
    JP Morgan
    3/2/2022Outperform
    Cowen
    2/25/2022$20.00 → $14.00Equal-Weight
    Morgan Stanley
    2/15/2022$36.00 → $20.00Equal-Weight
    Morgan Stanley
    1/6/2022$61.00 → $12.00Buy → Hold
    Stifel
    1/6/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berkeley Lights downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

      8/10/22 9:27:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by BTIG Research

      BTIG Research downgraded Berkeley Lights from Buy to Neutral

      8/10/22 7:24:20 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by JP Morgan with a new price target

      JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

      8/10/22 6:23:47 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

      2/8/24 5:58:45 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Berkeley Lights Inc.

      SC 13G - PhenomeX Inc. (0001689657) (Subject)

      8/28/23 5:04:18 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - PhenomeX Inc. (0001689657) (Subject)

      5/5/23 11:52:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

      EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

      2/13/23 4:30:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results

      EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

      1/9/23 4:02:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:42:49 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:41:09 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:32:22 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BLI
    SEC Filings

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Berkeley Lights Inc.

      15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/12/23 9:00:26 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POSASR filed by Berkeley Lights Inc.

      POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:16:24 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Berkeley Lights Inc.

      S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:06:56 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Announces Appointment of Scott Chaplin as Chief Legal Officer

      EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

      9/19/22 8:43:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

      EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

      8/1/22 8:35:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care